Cited 18 times in
Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장양수 | - |
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2015-04-23T16:38:48Z | - |
dc.date.available | 2015-04-23T16:38:48Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100963 | - |
dc.description.abstract | Zotarolimus-eluting stents (ZESs) demonstrated greater in-segment late luminal loss and in-segment binary restenosis rates compared to sirolimus-eluting stents (SESs) in several studies. However, no data are available in direct comparison between the clinical outcomes of the 2 stents in unselected patients with ST-segment elevation acute myocardial infarction (STEMI). The aim of the present study was to compare the clinical outcomes of ZESs and SESs in real-world patients with STEMI. A total of 873 patients with STEMI (306 patients in the ZES group and 567 patients in the SES group) were enrolled in a nationwide prospective Korea Acute Myocardial Infarction Registry (KAMIR) from January 2007 to January 2008. The primary end points were major adverse cardiac events, a composite of all causes of death, myocardial infarction, and target lesion revascularization during a 12-month clinical follow-up. During 1 year of follow-up, the primary end points occurred in 140 patients (16.0%). The use of glycoprotein IIb/IIIa inhibitors and the occurrence of multivessel disease were more common in the SES group. The SES group had a significantly lower incidence of major adverse cardiac events (hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.07 to 2.16, p = 0.02), target lesion revascularization (HR 2.16, 95% CI 1.01 to 4.59, p = 0.046), and target vessel revascularization (HR 2.24, 95% CI 1.18 to 4.24, p = 0.013). However, no significant differences were found in death or myocardial infarction (HR 1.37, 95% CI 0.91 to 2.05, p = 0.129). In conclusion, SESs provided superior angiographic outcomes, translating into better clinical outcomes and negating any change in STEMI patient safety profiles compared to ZESs. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 813~818 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Angioplasty, Balloon, Coronary* | - |
dc.subject.MESH | Coronary Angiography | - |
dc.subject.MESH | Coronary Restenosis/diagnostic imaging | - |
dc.subject.MESH | Drug-Eluting Stents*/adverse effects | - |
dc.subject.MESH | Electrocardiography* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Myocardial Infarction/diagnostic imaging | - |
dc.subject.MESH | Myocardial Infarction/drug therapy | - |
dc.subject.MESH | Myocardial Infarction/physiopathology | - |
dc.subject.MESH | Myocardial Infarction/therapy* | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Thrombosis/diagnostic imaging | - |
dc.title | Comparison of outcomes between Zotarolimus- and sirolimus-eluting stents in patients with ST-segment elevation acute myocardial infarction. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hyun Kuk Kim | - |
dc.contributor.googleauthor | Myung Ho Jeong | - |
dc.contributor.googleauthor | Young Keun Ahn | - |
dc.contributor.googleauthor | Jong Hyun Kim | - |
dc.contributor.googleauthor | Shung Chull Chae | - |
dc.contributor.googleauthor | Young Jo Kim | - |
dc.contributor.googleauthor | Seung Ho Hur | - |
dc.contributor.googleauthor | In Whan Seong | - |
dc.contributor.googleauthor | Taek Jong Hong | - |
dc.contributor.googleauthor | Dong Hoon Choi | - |
dc.contributor.googleauthor | Myeong Chan Cho | - |
dc.contributor.googleauthor | Chong Jin Kim | - |
dc.contributor.googleauthor | Ki Bae Seung | - |
dc.contributor.googleauthor | Wook Sung Chung | - |
dc.contributor.googleauthor | Yang Soo Jang | - |
dc.contributor.googleauthor | Seung Woon Rha | - |
dc.contributor.googleauthor | Jang Ho Bae | - |
dc.contributor.googleauthor | Jeong Gwan Cho | - |
dc.contributor.googleauthor | Seung Jung Park | - |
dc.identifier.doi | 10.1016/j.amjcard.2009.11.009 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A04053 | - |
dc.relation.journalcode | J00071 | - |
dc.identifier.eissn | 1879-1913 | - |
dc.identifier.pmid | 20211324 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0002914909026794 | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.citation.volume | 105 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 813 | - |
dc.citation.endPage | 818 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, Vol.105(6) : 813-818, 2010 | - |
dc.identifier.rimsid | 54084 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.